Biopharmaceutical company DiscGenics is enrolling 24 patients in a clinical study for the treatment of degenerative disc disease, reports HJ News.
The trial will study the efficacy of IDCT — an allogenic, injectable disc cell therapy — in treating mild to moderate degenerative disc disease.
An independent data safety monitoring company gave the all-clear after it completed a final mid-trial safety review following the treatment of the first six subjects in the high dose study group.
DiscGenics plans to treat a total of 60 subjects in the clinical study.